Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru

BMC Public Health

Volumn 13, Issue 1, 2013, Pages

  Gomez, Jorge Alberto ^a,b   Tirado, Juan Carlos ^b   Navarro Rojas, Aldo Amador ^c   Castrejon Alba, Maria Mercedes ^d   Topachevskyi, Oleksandr ^e  

^a GSK Argentina   (Argentina)

^b Complejo Hospitalario San Pablo Lima ^*  (Argentina)

^c GSK Peru Lima   (Peru)

^d GLAXOSMITHKLINE   (United Kingdom)

^e GSK   (Belgium)

Author keywords

Acute otitis media; Cost effectiveness; Non typeable Haemophilus influenzae; Peru; Pneumococcal disease; Pneumococcal vaccines

Indexed keywords

PNEUMOCOCCUS VACCINE; VACCINE;

ARTICLE; CHILD; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; ECONOMICS; HUMAN; INFANT; PERU; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; PNEUMOCOCCAL INFECTIONS;

CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; HUMANS; INFANT; MARKOV CHAINS; MODELS, STATISTICAL; PERU; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUALITY-ADJUSTED LIFE YEARS; VACCINES, CONJUGATE;

EID: 84886568960     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-13-1025     Document Type: Article

References (55)

1. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, Hib and Pneumococcal Global Burden of Disease Study Team, Lancet 2009 374 9693 893 902 10.1016/S0140-6736(09)61204-6 19748398
2. The burden of pneumococcal disease among Latin American and Caribbean children: review of the evidence. Valenzuela MT, O'Loughlin R, De La Hoz F, Gomez E, Constenla D, Sinha A, Valencia JE, Flannery B, De Quadros CA, Rev Panam Salud Publica 2009 25 3 270 279 19454155
3. Ministerio de Salud: Resolución Ministerial No 457-2009, [ftp://ftp2.minsa.gob.pe/normaslegales/2009/RM457-2009.pdf]
4. Ministerio de Salud, Convenio de cooperación técnica entre la Organización Panamericana de la Salud (OPS) y el Ministerio de Salud de la República del Peru (MINSA) para la adquisición de vacunas, jeringas y otros insumos relacionados [ftp://ftp2.minsa.gob.pe/descargas/ Transparencia/01InformacionInst/archivolegaldigital/Convenio2012/ Conv002-2012-MINSA.pdf]
5. World Health Organization, WHO Vaccine Preventable Diseases Monitoring System. 2011 Global summary [ http://apps.who.int/immunization-monitoring/ globalsummary/countries?countrycriteria[country][]=PER&commit=OK ]
6. Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multicountry analysis. Talbird SE, Taylor TN, Caporale J, Ismaila AS, Gomez J, Vaccine 2010 28 Suppl 6 14 G22 21075265
7. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: synflorix. Prymula R, Schuerman L, Expert Rev Vaccines 2009 8 11 1479 1500 10.1586/erv.09.113 19863240
8. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®]. Duggan ST, Drugs 2010 70 15 1973 1986 10.2165/11205110- 000000000-00000 20883054
9. Bolaños Díaz R, Mezones-Holguín E, Fiestas Solórzano V, Suárez Moreno V, Sanabria C, Evaluación económica de las vacunas hepta-, deca- y trece-valente para la prevención de neumonía asociada al Streptococcus pneumoniae en niños menores de 5 años en el Perú [ http://www.ins.gob.pe/ repositorioaps/0/4/jer/evidencias/Nota%20t%C3%A9cnica-6- Eval%20econ%20de%20las%20vacunas%20hepta-,%20deca-%20y%20trece-valente.pdf ]
10. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? Standaert B, Demarteau N, Talbird S, Mauskopf J, Vaccine 2010 28 Suppl 6 30 G38 21075268
11. Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise. Knerer G, Ismaila A, Pearce D, J Med Econ 2012 15 1 61 76 10.3111/13696998.2011.622323 22026590
12. Instituto Nacional de Estadística e Informática, Cuadro n 1: Población total, por área urbana y rural, y sexo, según departamento, provincia, distrito y edades simples [ http://desa.inei.gob.pe/ censos2007/tabulados/ ]
13. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, Schuerman L, Lancet 2006 367 9512 740 748 10.1016/S0140-6736(06)68304-9 16517274
14. A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. García Martí S, Colantonio L, Bardach A, Galante J, Lopez A, Caporale J, Knerer G, Gomez JA, Augustovski F, Pichon Riviere A, Cost Effectiveness and Resource Allocation 2013 11 21 doi:10.1186/1478-7547-11-21 10.1186/1478-7547-11-21 24004943
15. Linstone HA, Turoff M, The Delphi Method: Techniques and Applications Addison-Wesley 2002
16. Incidence of acute otitis media (AOM) and community acquired pneumonia (CAP) in a Brazilian community level primary care services (PCS) [abstract]. Cintra O, Iwamoto M, Iwamoto M, Delcaro L, Domingos J, Paula F, Ferraz I, Matsuno A, Arruda E, Pediatr Infect Dis J 2009 28 6 165
17. Patrones de prescripción de antimicrobianos en infecciones respiratorias agudas: encuesta en la población rural / Patterns of antimicrobial-drug prescriptions in acute respiratory infections: survey performed in the Mexican rurar area. Gutiérrez Trujillo G, Martínez González MC, Guiscafré Gallardo H, Gómez GP, Munoz O, Rev Fac Med UNAM 1989 32 4 134 136
18. Frecuencia de otitis media aguda en menores de 5 anos bajo control. Lopez I, Sepulveda H, Valdez I, Revista Pediatria (Santiago) 1998 41 21 25
19. Haemophilus influenzae: a significant pathogen in acute otitis media. Leibovitz E, Jacobs MR, Dagan R, Pediatr Infect Dis J 2004 23 12 1142 1152 15626953
20. [Characterization of invasive isolates of S. pneumoniae, H. influenzae, and N. meningitidis in Latin America and the Caribbean: SIREVA II, 2000-2005]. Gabastou JM, Agudelo CI, Brandileone MC, Castaneda E, de Lemos AP, Di Fabio JL, Grupo de Laboratorio de SIREVA II, Rev Panam Salud Publica 2008 24 1 1 15 10.1590/S1020-49892008000700001 18764989
21. de la Salud OP, Informe Regional de SIREVA II, 2006. Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesos invasores [ http://www.paho.org/Spanish/AD/THS/EV/labs- Sireva-II-2006.pdf ]
22. Organización Panamerica de la Salud, Informe Regional de SIREVA II: datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesos invasores, 2000-2005 [ http://www.paho.org/ Spanish/AD/THS/EV/LABS-Sireva.pdf ]
23. Setting standards for effectiveness: a comparison of expert panels and decision analysis. Bernstein SJ, Hofer TP, Meijler AP, Rigter H, Int J Qual Health Care 1997 9 4 255 263 10.1093/intqhc/9.4.255 9304424
24. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A, Lancet 2006 368 9546 1495 1502 10.1016/S0140-6736(06) 69637-2 17071283
25. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, Hackell J, Pediatr Infect Dis J 2002 21 9 810 815 10.1097/00006454-200209000- 00005 12352800
26. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World health organization standardized interpretation of chest radiographs. Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, Lewis E, Ray P, Lee J, Pediatr Infect Dis J 2006 25 9 779 781 10.1097/01.inf.0000232706.35674. 2f 16940833
27. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, Vaccine Trialists Group, N Engl J Med 2003 349 14 1341 1348 10.1056/NEJMoa035060 14523142
28. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA, Gambian Pneumococcal Vaccine Trial Group, Lancet 2005 365 9465 1139 1146 10.1016/S0140-6736(05)71876-6 15794968
29. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Madhi SA, Kuwanda L, Cutland C, Klugman KP, Clin Infect Dis 2005 40 10 1511 1518 10.1086/429828 15844075
30. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Lucero MG, Nohynek H, Williams G, Tallo V, Simoes EA, Lupisan S, Sanvictores D, Forsyth S, Puumalainen T, Ugpo J, Lechago M, de Campo M, Abucejo-Ladesma E, Sombrero L, Nissinen A, Soininen A, Ruutu P, Riley I, Makela HP, Pediatr Infect Dis J 2009 28 6 455 462 10.1097/INF.0b013e31819637af 19483514
31. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreno RA, Nohynek H, Riley ID, Makela H, Cochrane Database Syst Rev 2009 4 CD004977
32. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty H, Karma P, Kohberger R, Siber G, Makela PH, Finnish Otitis Media Study Group, N Engl J Med 2001 344 6 403 409 10.1056/NEJM200102083440602 11172176
33. Sáez-Llorens X, Tregnaghi MW, López P, Abate H, Pósleman A, Cortes-Barbosa C, Carabajal C, Calvo A, Wong D, Falaschi A, Gómes C, Caicedo Y, Leandro A, Avakian J, Esquivel R, Sierra A, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Ruiz Guiñazú J, Ortega-Barría E, Yarzábal JP, Schuerman L, Design/setting of COMPAS: a Latin American trial evaluating the efficacy of 10-valent pneumococcal non-typable Haemophilus influenza protein-D conjugate vaccine (PHiD-CV) The Hague, The Netherlands: 29th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID) 2011
34. Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, Tregnaghi M, Sierra A, Márquez V, Rodriguez M, Troitiño M, Rüttimann R, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Ruiz GJ, Ortega-Barría E, Yarzábal JP, Schuerman L, Evidencia de la eficacia de la vacuna decavalente antineumococcica conjugada a la proteína D del Haemophilus influenzae no tipificable (PHiD-CV por su siglas en inglés) frente a la neumonía adquirida en la comunidad en América Latina: resultados del estudio COMPAS Punta Cana, Republica Dominicana: XIV Congreso Latinoamericano de Infectología Pediátrica (SLIPE) 2011
35. Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, Tregnaghi M, Sierra A, Márquez V, Rodriguez M, Troitiño M, Rüttimann R, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Ruiz Guiñazú J, Ortega-Barría E, Yarzábal JP, Schuerman L, Evaluating the efficacy of 10-valent pneumococcal non-typable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) against community-adquired pneumonia in Latin America The Hague, The Netherlands: 29th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID) 2011
36. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsene JP, Lommel P, Dieussaert I, Schuerman L, Pediatr Infect Dis J 2009 28 4 Suppl 66 S76 19325449
37. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, Gatchalian S, Dieussaert I, Schuerman L, Pediatr Infect Dis J 2009 28 4 Suppl 89 S96 19325451
38. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T, Beall B, Shelly MA, Mahon BE, Nahm MH, Active Bacterial Core Surveillance Team, J Infect Dis 2008 198 12 1818 1822 10.1086/593339 18983249
39. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? Hausdorff WP, Hoet B, Schuerman L, BMC Pediatr 2010 10 4 10.1186/1471-2431-10-4 20122261
40. European Medicines Agency (EMEA) Committee For Medicinal Products For Human Use (CHMP), Guideline on clinical evaluation of new vaccines [ http://www.emea.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003870.pdf ]
41. Epidemiology of acute otitis media in children of Latin America and the Caribbean: a systematic review and meta-analysis. Bardach A, Ciapponi A, Garcia-Marti S, Glujovsky D, Mazzoni A, Fayad A, Colindres RE, Gentile A, Int J Pediatr Otorhinolaryngol 2011 75 9 1062 1070 10.1016/j.ijporl.2011.05.014 21665297
42. Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay. Constenla DO, Rev Panam Salud Publica 2008 24 2 101 112 19062601
43. Parents' utilities for outcomes of occult bacteremia. Bennett JE, Sumner W 2nd, Downs SM, Jaffe DM, Arch Pediatr Adolesc Med 2000 154 1 43 48 10632249
44. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Oh PI, Maerov P, Pritchard D, Knowles SR, Einarson TR, Shear NH, Clin Ther 1996 18 1 160 182 10.1016/S0149-2918(96)80188-3 8851461
45. Cost-utility analysis of patient care in children with meningeal signs. Oostenbrink R, Oostenbrink JB, Moons KG, Derksen-Lubsen G, Essink-Bot ML, Grobbee DE, Redekop WK, Moll HA, Int J Technol Assess Health Care 2002 18 3 485 496 12391942
46. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Morrow A, De Wals P, Petit G, Guay M, Erickson LJ, Can J Infect Dis Med Microbiol 2007 18 2 121 127 18923713
47. International Monetary Fund, World Economic and Financial Surveys, World Economic Outlook Database [ http://www.imf.org/external/pubs/ft/weo/2010/02/ weodata/index.aspx ]
48. Sachs JD, Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health [ http://whqlibdoc.who.int/publications/2001/924154550X.pdf ]
49. World Health Organization, The World Health report 2002. Reducing risks, promoting healthy life [ http://www.who.int/whr/2002/en/whr02-en.pdf ]
50. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. Centers for Disease Control and Prevention (CDC), MMWR Morb Mortal Wkly Rep 2005 54 36 893 897 16163262
51. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. Centers for Disease Control and Prevention (CDC), MMWR Morb Mortal Wkly Rep 2008 57 6 144 148 18272956
52. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, Schuerman L, Kilpi TM, Lancet 2013 381 9862 214 222 10.1016/S0140-6736(12)61854-6 23158882
53. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines]. Mucino-Ortega E, Mould-Quevedo JF, Farkouh R, Strutton D, Value Health 2011 14 5 Suppl 1 65 S70 21839902
54. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Uruena A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, Jimenez SG, Jauregui B, Clark AD, Diosque M, Vizzotti C, Vaccine 2011 29 31 4963 4972 10.1016/j.vaccine.2011.04.111 21621575
55. Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children. Castaneda-Orjuela C, Alvis-Guzman N, Velandia-Gonzalez M, De la Hoz-Restrepo F, Vaccine 2012 30 11 1936 1943 10.1016/j.vaccine.2012.01.031 22266291